Research
KPV in inflammation research
Inflammation models in which KPV has been studied, from 1980s fever and edema work to cytokine and NF-κB assays, with what each measured.
By the KPV Peptide editorial team · Last reviewed · Editorial review: approved by Ryan DeLauz (bulk sign-off in chat, 2026-11-11)
Short answer
KPV has been studied in inflammation models since 1984, first in fever and swelling experiments in rabbits and mice, later in cytokine, nitric-oxide and NF-κB assays in cultured cells. The work is entirely preclinical; FDA found no human data [FDA briefing 2026].
1980s–1990s: fever and swelling
The tripeptide reduced pyrogen-induced fever in rabbits, more weakly than full α-MSH [Richards 1984], and longer fragments added back potency [Deeter 1988]. In mice it reduced irritant-induced ear swelling [Hiltz 1989], and a D-valine analogue blunted inflammation caused by IL-1β, IL-6 and TNF-α but not by LTB4, PAF or IL-8 [Hiltz 1992].
2000s: separating KPV from α-MSH
A 2003 study found KPV reduced neutrophil influx in mouse peritonitis without raising cAMP or acting through melanocortin receptors, and proposed inhibition of IL-1β functions instead [Getting 2003]. Cell studies measured lower cytokines and nitric oxide in microglia [Delgado 1998] and lower NF-κB activity in airway epithelium [Land 2012]. A D-proline analogue reduced NF-κB subunit translocation in alveolar cells [Haddad 2001].
Studies in this area
| Study | Model | What was measured | Limitations | Grade |
|---|---|---|---|---|
| Richards 1984 Peptides Systemic inflammation and fever models | Animal Rabbit (leukocytic-pyrogen fever) | Measured body-temperature response to pyrogen in rabbits given the tripeptide centrally or peripherally; the tripeptide reduced fever with lower potency than full-length alpha-MSH. | 1984 study; sample size not stated in the abstract; potency lower than the parent hormone. | Evidence grade C |
| Deeter 1988 Peptides Systemic inflammation and fever models | Animal Rabbit (IL-1 fever), intracerebroventricular | Compared fever reduction by alpha-MSH fragments (11-13, 10-13, 8-13); all reduced fever dose-dependently and none matched alpha-MSH(1-13). | Acetylated, amidated analogue rather than native KPV; central administration only. | Evidence grade C |
| Hiltz 1989 FASEB J Skin and keratinocyte models · Systemic inflammation and fever models | Animal Mouse (picryl chloride ear swelling) | Measured irritant-induced ear swelling in mice; the tripeptide reduced swelling in a dose-related fashion. | Single irritant model; sample size not in abstract. | Evidence grade C |
| Hiltz 1990 Peptides Skin and keratinocyte models · Systemic inflammation and fever models | Animal Mouse (paw edema; contact sensitivity) | Measured paw edema and contact-sensitivity responses in mice; MSH peptides including the tripeptide reduced both. | Abstract does not separate tripeptide results from the full hormone in detail. | Evidence grade C |
| Hiltz 1992 Cytokine Systemic inflammation and fever models | Animal Mouse (cytokine-induced ear and paw inflammation) | Measured inflammation induced by IL-1 beta, IL-6, TNF-alpha, LTB4, PAF and IL-8; the analogue inhibited the cytokine-driven responses but not LTB4, PAF or IL-8. | D-valine analogue, not native KPV. | Evidence grade C |
| Uehara 1992 Eur J Pharmacol Systemic inflammation and fever models | Animal Rodent IL-1-induced anorexia model, intracerebroventricular (species not given in abstract) | Measured food intake after central IL-1; the tripeptide blocked IL-1-induced anorexia at the higher of two doses only. | Central administration; two doses only. | Evidence grade C |
| Delgado 1998 J Leukoc Biol Neuroinflammation models | In vitro Murine microglial cell line N9 (LPS + IFN-gamma) | Measured TNF-alpha, IL-6 and nitric oxide output from stimulated microglia; melanocortin peptides including the tripeptide reduced them concentration-dependently. | Single immortalised cell line. | Evidence grade D |
| Catania 1998 Peptides Systemic inflammation and fever models | Ex vivo Whole blood from people with HIV, stimulated with LPS | Measured IL-1 and TNF-alpha production in donated blood samples; melanocortins including the tripeptide reduced both concentration-dependently. | Ex vivo blood samples; no peptide was given to any person. | Evidence grade D |
| Galimberti 1999 Biochem Biophys Res Commun Neuroinflammation models | In vitro Murine microglia (beta-amyloid + IFN-gamma) | Measured nitrite, TNF-alpha and iNOS/TNF-alpha mRNA in stimulated microglia; both alpha-MSH and the tripeptide reduced them. | Cell line only. | Evidence grade D |
| Barcellini 2000 J Leukoc Biol Systemic inflammation and fever models | In vitro Human promonocytic U1 cells; monocyte-derived macrophages | Measured HIV-1 p24 release and NF-kappaB activation in infected cells; KPV reduced viral expression and NF-kappaB activation. | Cell culture only. | Evidence grade D |
| Mandrika 2001 Biochem Pharmacol Systemic inflammation and fever models | In vitro RAW 264.7 macrophages (LPS/IFN-gamma) | Measured nitric oxide output and NF-kappaB nuclear translocation; the tripeptide inhibited both, and the study examined MC1 receptor binding, which FDA later cited as evidence KPV does not displace alpha-MSH. | Single murine cell line. | Evidence grade D |
| Haddad 2001 Biochem J Airway epithelium | In vitro Fetal alveolar type II epithelial cells (LPS) | Measured nuclear localisation of NF-kappaB subunits p50, p65 and c-Rel; the D-proline analogue suppressed it dose-dependently. | D-proline analogue, not native KPV; fetal cell model. | Evidence grade D |
| Getting 2003 J Pharmacol Exp Ther Systemic inflammation and fever models | Animal Mouse (urate crystal and IL-1 beta peritonitis; MC1R e/e mice) plus macrophages in vitro | Measured neutrophil accumulation in peritonitis models; KPV reduced it, the MC3/4 antagonist SHU9119 did not block it, KPV did not raise cAMP, and the effect persisted in MC1R-deficient mice. | Peritonitis models; mechanism inferred by exclusion. | Evidence grade C |
| Muceniece 2003 Peptides Systemic inflammation and fever models | In vitro RAW 264.7 macrophages; B16-F1 cells; MCR-expressing insect cells | Measured melanocortin-receptor binding, cAMP and nitric oxide; the tripeptides did not bind MCRs or raise cAMP but dose-dependently inhibited stimulated NO production. | Cell assays; includes non-native cyclic analogues. | Evidence grade D |
| Land 2012 Int J Physiol Pathophysiol Pharmacol Airway epithelium | In vitro Human bronchial epithelial cells 16HBE14o- (TNF-alpha, RSV) | Measured NF-kappaB reporter activity, MMP-9, IL-8 and eotaxin; KPV reduced them and the study linked this to inhibition of p65RelA nuclear import at the importin-alpha3 site. | Single immortalised cell line; single-author study. | Evidence grade D |
| Schaible 2013 PLoS One Neuroinflammation models | Animal Mouse controlled cortical impact (traumatic brain injury model) | Measured secondary lesion volume, microglial activation and neuronal apoptosis; lesion volume and apoptosis markers were lower, while TNF-alpha and IL-1 beta expression did not change. | Single time-point administration; mixed inflammatory readouts. | Evidence grade C |
| Cheng 2026 Sci Adv Intestinal inflammation models · Airway epithelium · Delivery and formulation | Animal Mouse colitis and acute lung injury models | Measured colonic accumulation and inflammatory endpoints; the conjugate reached 3.8-fold higher colonic accumulation than free KPV. | Prodrug conjugate, not free KPV. | Evidence grade C |
References
- Richards DB, Lipton JM (1984). Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides. PubMed 6333677 · doi:10.1016/0196-9781(84)90027-5[Animal, grade C]
- Deeter LB, Martin LW, Lipton JM (1988). Antipyretic properties of centrally administered alpha-MSH fragments in the rabbit. Peptides. PubMed 2854626 · doi:10.1016/0196-9781(88)90193-3[Animal, grade C]
- Hiltz ME, Lipton JM (1989). Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. PubMed 2550304[Animal, grade C]
- Hiltz ME, Catania A, Lipton JM (1992). Alpha-MSH peptides inhibit acute inflammation induced in mice by rIL-1 beta, rIL-6, rTNF-alpha and endogenous pyrogen but not that caused by LTB4, PAF and rIL-8. Cytokine. PubMed 1325196 · doi:10.1016/1043-4666(92)90073-z[Animal, grade C]
- Getting SJ, Schiöth HB, Perretti M (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. PubMed 12750433 · doi:10.1124/jpet.103.051623[Animal, grade C]
- Delgado R, Carlin A, Airaghi L et al. (1998). Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. J Leukoc Biol. PubMed 9620667 · doi:10.1002/jlb.63.6.740[In vitro, grade D]
- Land SC (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. PubMed 22837805[In vitro, grade D]
- Haddad JJ, Lauterbach R, Saadé NE et al. (2001). Alpha-melanocyte-related tripeptide, Lys-d-Pro-Val, ameliorates endotoxin-induced nuclear factor kappaB translocation and activation: evidence for involvement of an interleukin-1beta193-195 receptor antagonism in the alveolar epithelium. Biochem J. PubMed 11256945 · doi:10.1042/0264-6021:3550029[In vitro, grade D]
- U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee (2026-07-23). FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate). Source[retrieved 2026-11-11]